Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 304 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Flush Clear all
Completed Not applicable Interventional

Effect of an Opioid Disposal Pouch Versus Usual Care on Post Discharge Disposal of Unused Medication

NCT04553588
View directory record Official record
Conditions
Drug Prescriptions
Interventions
Disposal pouch
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 2 Interventional Results available

Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics

NCT00605904
View directory record Official record
Conditions
Alcoholism
Interventions
Acamprosate, Yohimbine, mCPP, Saline
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Oct 24, 2026, 2:38 AM EDT
Recruiting Not applicable Interventional

Building Access to Food Through Systems and Solidarity

NCT05381766
View directory record Official record
Conditions
Diet Habit
Interventions
CSA Model
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 1 Interventional

Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases

NCT01447056
View directory record Official record
Conditions
Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphoproliferative Disorder, Nasopharyngeal Carcinoma, Leiomyosarcoma, Severe Chronic Active EBV (SCAEBV)
Interventions
LMP specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 24, 2026, 2:38 AM EDT
Completed No phase listed Observational

Portal Blood Flushes in the Peri-Reperfusion Stage of Liver Transplantation

NCT03563404
View directory record Official record
Conditions
Liver Disease
Interventions
Not listed
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Optical Imaging Measurement of Intravascular Solution Efficacy Trial

NCT01743872
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Contrast Injection, Dextran Injection, CO2 Injection, Heparinized Normal Saline Injection
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 24, 2026, 2:38 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Goji Berry and Vasomotor Symptoms Pilot Study

NCT07660315
View directory record Official record
Conditions
Vasomotor Symptoms
Interventions
Goji Berry Juice Powder, Goji Berry Powder
Other
Lead sponsor
University of California, Davis
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

NCT03497442
View directory record Official record
Conditions
Flushing, Alcohol-Related Disorders, Aldehyde Dehydrogenase Deficiency
Interventions
Brimonidine Tartrate, Placebo Vehicle Gel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

An Exploratory, Open Label, Single Center Study of [F-18]HX4

NCT00606424
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
20 mCi dose for a 50 kg individual of [F-18]HX4
Drug
Lead sponsor
Siemens Molecular Imaging
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 2, 2009 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exposure Therapy for Auditory Sensitivity in Autism

NCT03206996
View directory record Official record
Conditions
Sensory Disorders, Autism, Autism Spectrum Disorder, Autism With High Cognitive Abilities, Autistic Behavior, Hyperacusis
Interventions
Exposure therapy, Psycho-education, Caregiver education/home program development
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
5 Years to 17 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 24, 2026, 2:38 AM EDT
Recruiting Phase 1Phase 2 Interventional

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT04851119
View directory record Official record
Conditions
Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Desmoid Fibromatosis, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Refractory Desmoid Fibromatosis, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Solid Pseudopapillary Neoplasm of the Pancreas, Wilms Tumor
Interventions
Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint, X-Ray Imaging
Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 30 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 3 Interventional Results available

Endometrial Safety Study

NCT00522873
View directory record Official record
Conditions
Postmenopause
Interventions
0.25mg DRSP / 0.5mg E2 (BAY86-4891), 0.5mg NETA / 1.0mg E2 (Activella)
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Chandler, Arizona • San Diego, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pre-oxygenation With Real Time End-tidal Oxygen Measurements Versus Single Breath Measurements

NCT03840486
View directory record Official record
Conditions
Rapid Sequence Intubation
Interventions
Non-rebreather mask (NRBM), Non-invasive ventilator mask (NIV), Nasal cannula EtO2 sensor, Oxygen (NRBM), Oxygen (NIV)
Device · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 24, 2026, 2:38 AM EDT
Terminated Phase 2 Interventional Results available

Ondansetron as a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial

NCT05378113
View directory record Official record
Conditions
Injection Site Irritation
Interventions
Ondansetron, Lidocaine
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 24, 2026, 2:38 AM EDT
Terminated Phase 4 Interventional

Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation

NCT06169735
View directory record Official record
Conditions
Parathyroid Dysfunction, Adenoma
Interventions
Indocyanine green, SPY Portable Handheld Imaging
Drug · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers

NCT01565343
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
New Haven, Connecticut • Hallandale, Florida • West Palm Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Oct 24, 2026, 2:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Preclinical Imaging Biomarkers of Alzheimer's Disease Neuropathology in Young Adults With Youth-onset Diabetes: a Proof-of-concept Study

NCT05350514
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetes, Youth Onset
Interventions
PI-2620 tracer
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Flushing Reduction Associated With Nitrates

NCT02714205
View directory record Official record
Conditions
Menopausal Hot Flashes
Interventions
transdermal nitroglycerin, Placebo
Drug
Lead sponsor
Alison Huang, MD
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
2
States / cities
Oakland, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Flushes and Sertraline Trial

NCT00283192
View directory record Official record
Conditions
Menopause-Hot Flashes
Interventions
Sertraline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2006 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects

NCT05425719
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Drug · Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
5
States / cities
Edgewater, Florida • Chicago, Illinois • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.

NCT05932732
View directory record Official record
Conditions
Cutis Laxa Facialis, Xeroderma
Interventions
HydraFacial Syndeo System, ReGen-GF, HydraFacial Elite MD System
Device · Drug
Lead sponsor
Austin Institute for Clinical Research
Network
Eligibility
30 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Houston, Texas • Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 24, 2026, 2:38 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging

NCT00623467
View directory record Official record
Conditions
Central Nervous System Diseases
Interventions
Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 24, 2026, 2:38 AM EDT
Terminated Phase 1 Interventional

Study of Satraplatin (JM-216) in Combination With Docetaxel

NCT00125411
View directory record Official record
Conditions
Tumors
Interventions
satraplatin and docetaxel
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Oct 24, 2026, 2:38 AM EDT
Recruiting No phase listed Observational

Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

NCT04579120
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[11C]-Pittsburgh Compound B ([11C]PiB), F 18 AV-1451 (Flortaucipir)
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 24, 2026, 2:38 AM EDT